Skip navigation

Pfizer to pay $491M to resolve drug marketing case

The U.S. Justice Department said Tuesday that drugmaker Pfizer Inc. will pay almost $491 million to resolve an investigation into illegal marketing of the organ transplant drug Rapamune by a company Pfizer later acquired. Full story

Alkermes profit plunges off but stock jumps

Irish drugmaker Alkermes PLC's fiscal-first quarter earnings were down about 67 percent compared to last year, when the Irish drugmaker booked $20 million in intellectual property license revenue. Full story

Earnings roundup: Boston Scientific, Pinnacle

Among the earnings stories for Thursday, July 25, from AP Business News: Full story

Lilly beats forecast, helped by drugs soon to face generics

(Reuters) - Eli Lilly and Co <LLY.N> reported higher-than-expected quarterly earnings, helped by cost cuts and strong sales growth of depression and impotence treatments that will soon lose patent protection, and the drugmaker raised its full-year profit forecast. Full story

Drugmaker Vivus settles with biggest shareholder

Obesity drugmaker Vivus has agreed to a settlement with its biggest shareholder, which has been fighting for greater control of the company. A long-time drug executive backed by the shareholder will become CEO and the board will be reconfigured. Full story

Exclusive: Pfizer not moving forward with Onyx bid: sources

NEW YORK (Reuters) - Pfizer Inc decided not to pursue a bid for Onyx Pharmaceuticals Inc this week, according to two people familiar with the matter, leaving Amgen Inc in the front position to buy the cancer drugmaker. Full story

Sponsored Links

Articles

Novartis lifts full-year outlook after competition delay

Vivus says victim of false statements, delays shareholder meet

Movers roundup: Alexion, Fly Leasing

Exclusive: Major Vivus shareholder to support activist's slate - source

Hi-Tech Pharmacal loses $4.6M in fourth quarter

Exclusive: Forest mulls bid for Irish drugmaker Elan - sources

Actavis to buy Warner Chilcott in $8.5 billion deal

FDA's Deborah Autor to join drugmaker Mylan

Merger of drugmakers Valeant, Actavis on hold: source

Bayer core earnings growth tempered by high feedstock costs

Related Photos

The logo of Germany's largest drugmaker Bayer HealthCare Pharmaceuticals is pictured on the front of its building in Berlin
The logo of Germany's largest drugmaker Bayer HealthCare Pharmaceuticals is pictured on the front of its building in Berlin

The logo of Germany's largest drugmaker Bayer HealthCare Pharmaceuticals is pictured on the front of its building in Berlin April 28, 2011. REUTERS/Fabrizio Bensch

A plant belonging to Germany's largest drugmaker Bayer is seen in Leverkusen
A plant belonging to Germany's largest drugmaker Bayer is seen in Leverkusen

A plant belonging to Germany's largest drugmaker Bayer is seen in Leverkusen January 30, 2013. REUTERS/Ina Fassbender

The logo of the Swiss drugmaker Roche is seen on a factory in Burgdorf
The logo of the Swiss drugmaker Roche is seen on a factory in Burgdorf

The logo of the Swiss drugmaker Roche is seen on a factory in Burgdorf near Bern November 17, 2010. REUTERS/Pascal Lauener

File picture showing a general view of Swiss drugmaker Novartis headquarters in Basel
File picture showing a general view of Swiss drugmaker Novartis headquarters in Basel

File picture showing a general view of Swiss drugmaker Novartis headquarters in Basel September 1, 2011. India's highest court has dismissed, April 1, 2013, Swiss drugmaker Novartis AG's petition seeking patent protection for its cancer drug Glivec, a serious blow to Western pharmaceutical firms whi